Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: sharecropper2 who wrote (1240)	12/2/1999 4:07:00 PM
From: Lighthouse	Read Replies (1) \| Respond to of 3202

The first mention of the 50,000 number that I saw was in the press release of November 22, 1999 dealing with PFE. So far I have not seen or read any analysis concerning the implications of those filings. IMHO I seriously doubt INCY will get the exclusive patents on 50,000 full length human genes. There have been a multitude of companies working on various parts of the project for years. The IP on full, partial and contested gene patents are a lawyer dream come true. This will take awhile to sort through. Still the hope/intent is that the intellectual abyss of intellectual property rights will force/encourage Big Pharma and Academia into database subscriptions with INCY. I have not been able to elict any comment on this point from the thread here. I have read many INCY reports detailing that INCY's next database iterations, LifeExpress, will deal with SNP's and their expression functions. BT Alex Brown thinks INCY will sign collaborations with Big Pharma once the SNP map/database hits critical mass. I am out of my league on that one, but this is an area where CRGN has been working for some time. Today it is racing ahead. Let the handicapping begin. Cheers,